Opium (Opioid) Addiction - Pipeline Review, H2 2018

Opium (Opioid) Addiction - Pipeline Review, H2 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Opium (Opioid) Addiction - Pipeline Review, H2 2018, provides an overview of the Opium (Opioid) Addiction (Central Nervous System) pipeline landscape.

Opioid Addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). This can lead to an inability for the body to stop pain because there are no endorphins to mask the pain initially. The degeneration of the nerve cells that reduce pain can lead to a physical dependence on opiates as an external supply source. Signs and symptoms include increased general anxiety, euphoria, psychosis, depression, high blood pressure, decreased appetite, physical agitation, difficulty sleeping and pain in the bones. The predisposing factors include age, a personal history of substance abuse, and family history of substance abuse, cigarette dependency and psychologic stress.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Opium (Opioid) Addiction - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Opium (Opioid) Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 4, 6, 2, 18, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 6 molecules, respectively.

Opium (Opioid) Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Opium (Opioid) Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Opium (Opioid) Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Opium (Opioid) Addiction (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Opium (Opioid) Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 5
Opium (Opioid) Addiction - Overview 6
Opium (Opioid) Addiction - Therapeutics Development 7
Opium (Opioid) Addiction - Therapeutics Assessment 16
Opium (Opioid) Addiction - Companies Involved in Therapeutics Development 24
Opium (Opioid) Addiction - Drug Profiles 34
Opium (Opioid) Addiction - Dormant Projects 106
Opium (Opioid) Addiction - Discontinued Products 107
Opium (Opioid) Addiction - Product Development Milestones 108
Appendix 115

List Of Tables


Number of Products under Development for Opium (Opioid) Addiction, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Opium (Opioid) Addiction - Pipeline by Adapt Pharma Ltd, H2 2018
Opium (Opioid) Addiction - Pipeline by Addex Therapeutics Ltd, H2 2018
Opium (Opioid) Addiction - Pipeline by Aoxing Pharmaceutical Company Inc, H2 2018
Opium (Opioid) Addiction - Pipeline by BioCorRx Inc, H2 2018
Opium (Opioid) Addiction - Pipeline by BioDelivery Sciences International Inc, H2 2018
Opium (Opioid) Addiction - Pipeline by Camurus AB, H2 2018
Opium (Opioid) Addiction - Pipeline by Fabentech SA, H2 2018
Opium (Opioid) Addiction - Pipeline by Indivior Plc, H2 2018
Opium (Opioid) Addiction - Pipeline by Insys Therapeutics Inc, H2 2018
Opium (Opioid) Addiction - Pipeline by iX Biopharma Ltd, H2 2018
Opium (Opioid) Addiction - Pipeline by Novartis AG, H2 2018
Opium (Opioid) Addiction - Pipeline by Omeros Corp, H2 2018
Opium (Opioid) Addiction - Pipeline by Opiant Pharmaceuticals Inc, H2 2018
Opium (Opioid) Addiction - Pipeline by Orexo AB, H2 2018
Opium (Opioid) Addiction - Pipeline by Pfizer Inc, H2 2018
Opium (Opioid) Addiction - Pipeline by Relmada Therapeutics Inc, H2 2018
Opium (Opioid) Addiction - Pipeline by Serina Therapeutics Inc, H2 2018
Opium (Opioid) Addiction - Pipeline by Syntropharma Ltd, H2 2018
Opium (Opioid) Addiction - Pipeline by Titan Pharmaceuticals Inc, H2 2018
Opium (Opioid) Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H2 2018
Opium (Opioid) Addiction - Dormant Projects, H2 2018
Opium (Opioid) Addiction - Discontinued Products, H2 2018

List Of Figures


Number of Products under Development for Opium (Opioid) Addiction, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Opium (Opioid) Addiction - Pipeline Review, H2 2018

Opium (Opioid) Addiction - Pipeline Review, H2 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Opium (Opioid) Addiction - Pipeline Review, H2 2018, provides an overview of the

USD 2000 View Report

Opium Withdrawal Syndrome Global Clinical Trials Review, H1, 2018

Opium Withdrawal Syndrome Global Clinical Trials Review, H1, 2018GlobalDatas clinical trial report, Opium Withdrawal Syndrome Global Clinical Trials Review, H1, 2018 provides an overview of Opium Withdrawal Syndrome clinical trials

USD 2500 View Report

Opium (Opioid) Addiction Global Clinical Trials Review, H1, 2018

Opium (Opioid) Addiction Global Clinical Trials Review, H1, 2018GlobalDatas clinical trial report, Opium (Opioid) Addiction Global Clinical Trials Review, H1, 2018 provides an overview of Opium (Opioid) Addiction clinical trials

USD 2500 View Report

Opium (Opioid) Addiction - Pipeline Review, H1 2018

Opium (Opioid) Addiction - Pipeline Review, H1 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Opium (Opioid) Addiction - Pipeline Review, H1 2018, provides an overview of the

USD 2000 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available